Major randomised trials in cancer-associated thrombosis treatment

TrialYearPatients nDrugs evaluatedMajor findings
CANTHANOX [35]2002146Enoxaparin versus warfarinStatistical tendency of warfarin to be more associated with major bleeding (p=0.09) and death (p=0.07) than enoxaparin.
CLOT [36]2003672Dalteparin versus warfarinDalteparin was superior to warfarin in VTE recurrence (p=0.002). No difference in major bleeding or mortality.
CATCH [37]2015900Tinzaparin versus warfarinStatistical tendency of VTE recurrence reduction with tinzaparin (p=07). No difference in major bleeding or mortality.
HOKUSAI-CANCER [45]20181046Edoxaban versus dalteparinEdoxaban was non-inferior to dalteparin. Statistical tendency of superiority of edoxaban in VTE recurrence reduction (p=0.09), statistically significant more major bleeding with edoxaban (p=0.04).
SELECT-D [47]2018406Rivaroxaban versus dalteparinStatistically significant less VTE recurrence (HR 0.43, 95% CI 0.19–0.99) and statistical tendency of more bleeding (HR 1.83, 95% CI 0.68–4.96) with rivaroxaban (oesophagus and gastro-oesophageal junction cancer patients excluded after inclusion of the first 220 patients)
CARAVAGGIO [48]2019 (expected)1168 (expected)Apixaban versus dalteparin?

VTE: venous thromboembolism.